These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11837793)

  • 21. DX-9065a inhibits proinflammatory events induced by gingipains and factor Xa.
    Matsushita K; Imamura T; Tomikawa M; Tancharoen S; Tatsuyama S; Maruyama I
    J Periodontal Res; 2006 Apr; 41(2):148-56. PubMed ID: 16499718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease.
    Becker RC; Alexander J; Dyke CK; Harrington RA
    Thromb Haemost; 2004 Dec; 92(6):1182-93. PubMed ID: 15583722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular endothelial tissue factor pathway inhibitor kinetics in culture following exposure to DX-9065a--a selective and direct factor Xa inhibitor.
    Becker RC; Alexander JH; Li Y; Robertson T; Kunitada S; Spencer FA; Yang H; Harrington RA
    J Thromb Thrombolysis; 2004 Dec; 18(3):193-7. PubMed ID: 15815881
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Roles of coagulation pathway and factor Xa in rat mesangioproliferative glomerulonephritis.
    Nomura K; Liu N; Nagai K; Hasegawa T; Kobayashi I; Nogaki F; Tanaka M; Arai H; Fukatsu A; Kita T; Ono T
    Lab Invest; 2007 Feb; 87(2):150-60. PubMed ID: 17179958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DX-9065a, a direct inhibitor of factor Xa.
    Kaiser B
    Cardiovasc Drug Rev; 2003; 21(2):91-104. PubMed ID: 12847561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A specific inhibitor of factor Xa, DX-9065a, exerts effective protection against experimental tumor induced disseminated intravascular coagulation in rats.
    Tanabe K; Terada Y; Shibutani T; Kunitada S; Kondo T
    Thromb Res; 1999 Oct; 96(2):135-43. PubMed ID: 10574591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers.
    Murayama N; Tanaka M; Kunitada S; Yamada H; Inoue T; Terada Y; Fujita M; Ikeda Y
    Clin Pharmacol Ther; 1999 Sep; 66(3):258-64. PubMed ID: 10511061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats.
    Hara T; Yokoyama A; Tanabe K; Ishihara H; Iwamoto M
    Thromb Haemost; 1995 Aug; 74(2):635-9. PubMed ID: 8584999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thrombin and factor Xa enhance neutrophil chemoattractant production after ischemia/reperfusion in the rat liver.
    Yamaguchi Y; Okabe K; Liang J; Ohshiro H; Ishihara K; Uchino S; Zhang JL; Hidaka H; Yamada S; Ogawa M
    J Surg Res; 2000 Jul; 92(1):96-102. PubMed ID: 10864488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats.
    Yamazaki M; Asakura H; Aoshima K; Saito M; Jokaji H; Uotani C; Kumabashiri I; Morishita E; Ikeda T; Matsuda T
    Semin Thromb Hemost; 1996; 22(3):255-9. PubMed ID: 8836010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enoxaparin and fondaparinux attenuates endothelial damage in endotoxemic rats.
    Iba T; Okamoto K; Ohike T; Tajirika T; Aihara K; Watanabe S; Kayhanian H
    J Trauma Acute Care Surg; 2012 Jan; 72(1):177-82. PubMed ID: 22310127
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial.
    Alexander JH; Yang H; Becker RC; Kodama K; Goodman S; Dyke CK; Kleiman NS; Hochman JS; Berger PB; Cohen EA; Lincoff AM; Burton JR; Bovill EG; Kawai C; Armstrong PW; Harrington RA;
    J Thromb Haemost; 2005 Mar; 3(3):439-47. PubMed ID: 15748230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant thrombomodulin improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat LPS model.
    Iba T; Aihara K; Watanabe S; Yanagawa Y; Takemoto M; Yamada A; Yang D
    Thromb Res; 2013 Apr; 131(4):295-9. PubMed ID: 23273403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.
    Alexander JH; Dyke CK; Yang H; Becker RC; Hasselblad V; Zillman LA; Kleiman NS; Hochman JS; Berger PB; Cohen EA; Lincoff AM; Saint-Jacques H; Chetcuti S; Burton JR; Buergler JM; Spence FP; Shimoto Y; Robertson TL; Kunitada S; Bovill EG; Armstrong PW; Harrington RA;
    J Thromb Haemost; 2004 Feb; 2(2):234-41. PubMed ID: 14995984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and biological activity of amidinobicyclic compounds (derivatives of DX-9065a) as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S; Kanaya N; Nagahara T; Yokoyama A; Inamura K; Yokoyama Y; Katakura S; Hara T
    Bioorg Med Chem; 2004 May; 12(9):2099-114. PubMed ID: 15080912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant tissue factor pathway inhibitor reduces lipopolysaccharide-induced pulmonary vascular injury by inhibiting leukocyte activation.
    Enkhbaatar P; Okajima K; Murakami K; Uchiba M; Okabe H; Okabe K; Yamaguchi Y
    Am J Respir Crit Care Med; 2000 Nov; 162(5):1752-9. PubMed ID: 11069808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Photodecarboxylation of DX-9065a, a new factor Xa inhibitor, in aqueous solution.
    Kawai Y; Matsubayashi K
    Chem Pharm Bull (Tokyo); 1998 Jan; 46(1):131-5. PubMed ID: 9468645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced endogenous thrombolysis induced by a specific factor Xa inhibitor, DX-9065a, evaluated in a rat arterial thrombolysis model in vivo.
    Hashimoto M; Onobayashi Y; Oiwa K; Giddings JC; Yamamoto J
    Thromb Res; 2002 Apr; 106(2):165-8. PubMed ID: 12182917
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of the novel direct factor Xa inhibitor DX-9065a on thrombin generation and inhibition among patients with stable atherosclerotic coronary artery disease.
    Becker RC; Alexander JH; Dyke C; Huang Y; Saint-Jacques H; Hasselblad V; Harrington RA; Bovill EG;
    Thromb Res; 2006; 117(4):439-46. PubMed ID: 15882894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential effects of DX-9065a, argatroban, and synthetic pentasaccharide on tissue thromboplastin inhibition test and dilute Russell's viper venom test.
    Gerbutavicius R; Iqbal O; Messmore HL; Wehrmacher WH; Hoppensteadt DA; Gerbutaviciene R; Griniute R; Fareed J
    Clin Appl Thromb Hemost; 2003 Oct; 9(4):317-23. PubMed ID: 14653441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.